Merck Ad5/HIV induces broad innate immune activation that predicts CD8⁺ T-cell responses but is attenuated by preexisting Ad5 immunity.
about
Glucopyranosyl lipid A adjuvant significantly enhances HIV specific T and B cell responses elicited by a DNA-MVA-protein vaccine regimenMethods and clinical development of adenovirus-vectored vaccines against mucosal pathogensDevelopment of Novel Adenoviral Vectors to Overcome Challenges Observed With HAdV-5-based ConstructsSystems Biology Approach for Cancer Vaccine Development and EvaluationSystems vaccinology: probing humanity's diverse immune systems with vaccines.Immune activation alters cellular and humoral responses to yellow fever 17D vaccineTime-Course Gene Set Analysis for Longitudinal Gene Expression DataProduction and purification of non replicative canine adenovirus type 2 derived vectors.Novel directions in HIV-1 vaccines revealed from clinical trialsA third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: First-in-human trial of ChAd63-KH.Manipulation of EAT-2 expression promotes induction of multiple beneficial regulatory and effector functions of the human innate immune system as a novel immunomodulatory strategySystems-level analysis of innate immunity.New gorilla adenovirus vaccine vectors induce potent immune responses and protection in a mouse malaria model.Analysis of HLA A*02 association with vaccine efficacy in the RV144 HIV-1 vaccine trial.Improved cytotoxic T-lymphocyte immune responses to a tumor antigen by vaccines co-expressing the SLAM-associated adaptor EAT-2.Infection with host-range mutant adenovirus 5 suppresses innate immunity and induces systemic CD4+ T cell activation in rhesus macaques.Optimization of a whole blood phenotyping assay for enumeration of peripheral blood leukocyte populations in multicenter clinical trials.Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili studyAntibody persistence and T-cell balance: two key factors confronting HIV vaccine development.Multiple low-dose challenges in a rhesus macaque AIDS vaccine trial result in an evolving host response that affects protective outcomeTranscriptomic profiling facilitates classification of response to influenza challenge.Human adenovirus 52 uses sialic acid-containing glycoproteins and the coxsackie and adenovirus receptor for binding to target cellsAntigen expression determines adenoviral vaccine potency independent of IFN and STING signaling.A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of an Adjuvanted HIV-1 Gag-Pol-Nef Fusion Protein and Adenovirus 35 Gag-RT-Int-Nef Vaccine in Healthy HIV-Uninfected African Adults.Plasma cytokine levels and risk of HIV type 1 (HIV-1) transmission and acquisition: a nested case-control study among HIV-1-serodiscordant couples.Six host-range restricted poxviruses from three genera induce distinct gene expression profiles in an in vivo mouse modelContinued Follow-Up of Phambili Phase 2b Randomized HIV-1 Vaccine Trial Participants Supports Increased HIV-1 Acquisition among Vaccinated Men.Transient IL-10 receptor blockade can enhance CD8(+) T cell responses to a simian adenovirus-vectored HIV-1 conserved region immunogenEarly Transcriptome Signatures from Immunized Mouse Dendritic Cells Predict Late Vaccine-Induced T-Cell Responses.Systems vaccinology: Enabling rational vaccine design with systems biological approaches.Antigen capsid-display on human adenovirus 35 via pIX fusion is a potent vaccine platform.Safety and Immunogenicity of the Recombinant BCG Vaccine AERAS-422 in Healthy BCG-naïve Adults: A Randomized, Active-controlled, First-in-human Phase 1 Trial.Development of prophylactic vaccines against HIV-1.Immunity to viruses: learning from successful human vaccinesVariability in the immune system: of vaccine responses and immune states.Systems biological approaches to measure and understand vaccine immunity in humans.Novel adjuvants & delivery vehicles for vaccines development: a road aheadMolecular signatures of antibody responses derived from a systems biology study of five human vaccinesA Comparative Phase I Study of Combination, Homologous Subtype-C DNA, MVA, and Env gp140 Protein/Adjuvant HIV Vaccines in Two Immunization Regimes.Vaccine nanoparticles for protection against HIV infection.
P2860
Q21089693-46BCB52C-B496-450E-AD08-DECB31F70A5DQ26750912-7FD66D40-D0EA-49ED-95D5-B312A3EC2CEBQ26782083-79F83F6B-7520-49FE-B4BF-F87D19213CECQ26782580-56592CB8-A22F-43B7-BF22-E2D26A16FAE2Q27690799-19C652CB-31FC-4792-A93A-DB4E67A32255Q28388716-77022071-B596-4C6D-A53F-680053398F9EQ30000087-95096427-C6BC-47A8-8790-05F804CB9412Q33640963-27E85DB9-A852-4FA3-B072-9A5B71AEFB7FQ33645528-6C2FE030-7987-45D7-A1E9-DAC15F5B5DD9Q33724960-01177C7A-CDA2-434C-BF80-21D6B37D33A6Q33749309-D92B50DA-8846-4EB9-89B2-2F863A2D9F0BQ33855179-76A27FB4-577E-4723-A1E6-23EE2173D810Q33868760-93B6236A-E2E1-4A1B-93DE-68F818D8B893Q34057942-1C05B0B2-BE86-4C09-92EA-B222E18DD1C5Q34080911-F0114456-3093-4DAA-92EE-B53E61961665Q34155550-298AE6C5-94B9-4EE7-B689-639E4D971180Q34225046-79296518-CCE2-4D59-A843-865869FD72B3Q34240204-87A3036F-16AB-41B0-89EC-B05A12F34A62Q34480617-8895E79D-B74F-4077-8E00-D89DCEAA78E5Q34593105-7CEB73CD-83A7-4981-8603-A150AFA8CFA5Q34798503-38AAC01F-874E-4068-BDCA-C79DDD2C9E4BQ35104823-80E88956-5C8A-4256-B0CC-4FFE7F8C9C58Q35183935-3CD18492-B389-48BE-931A-0727079CC3DCQ35593139-22E37B93-A446-4C49-971A-AB18AEEC7C60Q35661895-023B0E1A-9DBF-442B-A346-696E3C6CB4FBQ35685675-32A27A63-F470-487E-82A3-A9EEF56A70CDQ35774494-1EE4BA6A-4533-48A0-8FEF-28856065F5A1Q35887443-D6990EAD-B277-47FA-A8F0-2A08F58447B7Q35964579-B0AC474C-1F3F-4535-978E-B2B29DFC59E1Q36090112-E046C17E-9DF2-4A8F-A1F7-BD16B0233601Q36330007-86DFAA3D-744E-4C37-BE45-1B5837D5407BQ37008729-ECEC3AEC-2675-4E1E-A30C-8F47F184BA13Q37042563-87255545-54D1-4551-A6EA-B11697FD3E0EQ37108439-25FC92DF-FAC1-4B3E-9C54-A9FF5DA106ECQ37211106-69CC99C3-0E21-4415-A609-EBF783DCD7E4Q37232564-19C91BE7-9188-48A3-95A5-6502907F321CQ37592383-3124EC80-2628-4689-87C7-01DEC1CBD6D2Q37625332-BF0B1309-7BB5-4294-9AB1-D9FB03DCAE2EQ37656908-DE660E6D-00AE-402E-A897-D5636B9E70B4Q38405327-8E8C27AA-A837-470D-94C3-BA3C69D8E99D
P2860
Merck Ad5/HIV induces broad innate immune activation that predicts CD8⁺ T-cell responses but is attenuated by preexisting Ad5 immunity.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Merck Ad5/HIV induces broad in ...... d by preexisting Ad5 immunity.
@ast
Merck Ad5/HIV induces broad in ...... d by preexisting Ad5 immunity.
@en
type
label
Merck Ad5/HIV induces broad in ...... d by preexisting Ad5 immunity.
@ast
Merck Ad5/HIV induces broad in ...... d by preexisting Ad5 immunity.
@en
prefLabel
Merck Ad5/HIV induces broad in ...... d by preexisting Ad5 immunity.
@ast
Merck Ad5/HIV induces broad in ...... d by preexisting Ad5 immunity.
@en
P2093
P2860
P356
P1476
Merck Ad5/HIV induces broad in ...... d by preexisting Ad5 immunity.
@en
P2093
Akshay T Krishnamurty
Alan Aderem
Alexander I Salter
Alicia Sato
Ann C Duerr
Cecilia A Morgan
Daniel E Zak
Devin J Adams
Eric R Peterson
Erica Andersen-Nissen
P2860
P304
P356
10.1073/PNAS.1208972109
P407
P577
2012-11-14T00:00:00Z